Genetic Technologies Limited (AU:GTG) has released an update.
Genetic Technologies Limited has reported a successful quarter with A$1.8m in cash receipts and a 500% increase in geneType commercial samples, indicating significant clinician adoption and a pathway to profitability. Their aggressive digital marketing strategy in the United States is expected to substantially boost sales by tapping into the rapidly growing DTC wellness testing market. Additionally, the company has launched innovative risk assessment tests and secured funding through shareholder approval and a direct offering post-quarter.
For further insights into AU:GTG stock, check out TipRanks’ Stock Analysis page.
